• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

炎症对骨髓增殖性肿瘤症状发展的影响。

Impact of Inflammation on Myeloproliferative Neoplasm Symptom Development.

作者信息

Geyer Holly L, Dueck Amylou C, Scherber Robyn M, Mesa Ruben A

机构信息

Division of Hospital Internal Medicine, Mayo Clinic, Scottsdale, AZ 85054, USA.

Department of Statistics, Mayo Clinic, Scottsdale, AZ 85054, USA.

出版信息

Mediators Inflamm. 2015;2015:284706. doi: 10.1155/2015/284706. Epub 2015 Oct 11.

DOI:10.1155/2015/284706
PMID:26538823
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4619953/
Abstract

Myeloproliferative neoplasms (essential thrombocythemia, ET; polycythemia vera, PV; myelofibrosis, MF) are monoclonal malignancies associated with genomic instability, dysregulated signaling pathways, and subsequent overproduction of inflammatory markers. Acknowledged for their debilitating symptom profiles, recent investigations have aimed to determine the identity of these markers, the upstream sources stimulating their development, their prevalence within the MPN population, and the role they play in symptom development. Creation of dedicated Patient Reported Outcome (PRO) tools, in combination with expanded access to cytokine analysis technology, has resulted in a surge of investigations evaluating the potential associations between symptoms and inflammation. Emerging data demonstrates clear relationships between individual MPN symptoms (fatigue, abdominal complaints, microvascular symptoms, and constitutional symptoms) and cytokines, particularly IL-1, IL-6, IL-8, and TNF-α. Information is also compiling on the role symptoms paradoxically play in the development of cytokines, as in the case of fatigue-driven sedentary lifestyles. In this paper, we explore the symptoms inherent to the MPN disorders and the potential role inflammation plays in their development.

摘要

骨髓增殖性肿瘤(原发性血小板增多症、真性红细胞增多症、骨髓纤维化)是与基因组不稳定、信号通路失调以及随后炎症标志物过度产生相关的单克隆恶性肿瘤。鉴于其令人衰弱的症状特征,最近的研究旨在确定这些标志物的身份、刺激其产生的上游来源、它们在骨髓增殖性肿瘤患者群体中的患病率,以及它们在症状发展中所起的作用。专门的患者报告结局(PRO)工具的创建,结合对细胞因子分析技术的更广泛应用,导致了大量评估症状与炎症之间潜在关联的研究。新出现的数据表明,个体骨髓增殖性肿瘤症状(疲劳、腹部不适、微血管症状和全身症状)与细胞因子,特别是白细胞介素-1、白细胞介素-6、白细胞介素-8和肿瘤坏死因子-α之间存在明确的关系。关于症状在细胞因子产生过程中所起的矛盾作用的信息也在不断积累,例如疲劳导致的久坐生活方式。在本文中,我们探讨了骨髓增殖性肿瘤疾病固有的症状以及炎症在其发展中可能发挥的作用。

相似文献

1
Impact of Inflammation on Myeloproliferative Neoplasm Symptom Development.炎症对骨髓增殖性肿瘤症状发展的影响。
Mediators Inflamm. 2015;2015:284706. doi: 10.1155/2015/284706. Epub 2015 Oct 11.
2
Assessing disease burden in patients with classic MPNs.评估经典骨髓增殖性肿瘤患者的疾病负担。
Best Pract Res Clin Haematol. 2014 Jun;27(2):107-19. doi: 10.1016/j.beha.2014.07.006. Epub 2014 Jul 18.
3
Inflammation and myeloproliferative neoplasms.炎症和骨髓增殖性肿瘤。
J Autoimmun. 2017 Dec;85:58-63. doi: 10.1016/j.jaut.2017.06.010. Epub 2017 Jun 30.
4
Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the United States: Findings from the MPN Landmark survey.美国骨髓增殖性肿瘤(MPN)患者与血液科医生/肿瘤内科医生在治疗目标和症状负担认知上的差异:MPN里程碑式调查结果
Cancer. 2017 Feb 1;123(3):449-458. doi: 10.1002/cncr.30325. Epub 2016 Sep 30.
5
GATA1 downregulation in prefibrotic and fibrotic stages of primary myelofibrosis and in the myelofibrotic progression of other myeloproliferative neoplasms.GATA1 在原发性骨髓纤维化的前纤维化和纤维化阶段以及其他骨髓增殖性肿瘤的骨髓纤维化进展中下调。
Leuk Res. 2021 Jan;100:106495. doi: 10.1016/j.leukres.2020.106495. Epub 2020 Dec 15.
6
Management of symptoms in polycythemia vera and essential thrombocythemia patients.真性红细胞增多症和原发性血小板增多症患者症状的管理。
Hematology Am Soc Hematol Educ Program. 2015;2015:340-8. doi: 10.1182/asheducation-2015.1.340.
7
Increased plasma nicotinamide phosphoribosyltransferase is associated with a hyperproliferative phenotype and restrains disease progression in MPN-associated myelofibrosis.血浆烟酰胺磷酸核糖基转移酶水平升高与增殖表型相关,并抑制 MPN 相关骨髓纤维化中的疾病进展。
Am J Hematol. 2016 Jul;91(7):709-13. doi: 10.1002/ajh.24388. Epub 2016 May 26.
8
miR-146a rs2431697 identifies myeloproliferative neoplasm patients with higher secondary myelofibrosis progression risk.miR-146a rs2431697 可识别出骨髓增殖性肿瘤患者中具有较高继发性骨髓纤维化进展风险者。
Leukemia. 2020 Oct;34(10):2648-2659. doi: 10.1038/s41375-020-0767-3. Epub 2020 Feb 27.
9
Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).慢性骨髓增殖性疾病(MPD)、原发性血小板增多症(ET)、真性红细胞增多症(PV)和慢性特发性骨髓纤维化(CIMF)的现行诊断标准。
Pathol Biol (Paris). 2007 Mar;55(2):92-104. doi: 10.1016/j.patbio.2006.06.002. Epub 2006 Aug 21.
10
Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia.慢性骨髓增殖性疾病的发病机制:真性红细胞增多症、原发性血小板增多症、特发性骨髓化生及慢性粒细胞白血病。
Semin Hematol. 1999 Jan;36(1 Suppl 2):3-8.

引用本文的文献

1
Management of Myeloproliferative Neoplasms: An Integrative Approach.骨髓增殖性肿瘤的管理:一种综合方法。
J Clin Med. 2025 Jul 17;14(14):5080. doi: 10.3390/jcm14145080.
2
DNA Methylation in Ph-Negative Myeloproliferative Neoplasms: Prognostic Role and Therapeutic Implications.阴性骨髓增殖性肿瘤中的DNA甲基化:预后作用及治疗意义
Curr Issues Mol Biol. 2025 Mar 26;47(4):227. doi: 10.3390/cimb47040227.
3
Potential application of the bulk RNA sequencing in routine MPN clinics.批量RNA测序在骨髓增殖性肿瘤常规临床中的潜在应用。
BMC Cancer. 2025 Apr 22;25(1):746. doi: 10.1186/s12885-025-13947-x.
4
Optimization of allogeneic hematopoietic cell transplantation for patients with myelofibrosis treated with ruxolitinib: eligibility, best practices, and improving transplant outcomes.芦可替尼治疗的骨髓纤维化患者异基因造血细胞移植的优化:入选标准、最佳实践及改善移植结局
Ann Hematol. 2025 Apr;104(4):2125-2141. doi: 10.1007/s00277-025-06270-9. Epub 2025 Mar 22.
5
Optimizing Care: Integrative Oncology in Myeloproliferative Neoplasm.优化护理:骨髓增殖性肿瘤的综合肿瘤学。
Curr Oncol Rep. 2024 Oct;26(10):1135-1145. doi: 10.1007/s11912-024-01568-9. Epub 2024 Jul 5.
6
Management of Patients with Early Myelofibrosis: A Discussion of Best Practices.早期骨髓纤维化患者的管理:最佳实践的讨论。
Curr Hematol Malig Rep. 2024 Jun;19(3):111-119. doi: 10.1007/s11899-024-00729-8. Epub 2024 Mar 5.
7
Revisiting Circulating Extracellular Matrix Fragments as Disease Markers in Myelofibrosis and Related Neoplasms.重新审视循环细胞外基质片段作为骨髓纤维化及相关肿瘤的疾病标志物
Cancers (Basel). 2023 Aug 29;15(17):4323. doi: 10.3390/cancers15174323.
8
Myeloproliferative neoplasms - blurring the lines between cancer and chronic inflammatory disorder.骨髓增殖性肿瘤——模糊癌症与慢性炎症性疾病之间的界限。
Front Oncol. 2023 Jun 9;13:1208089. doi: 10.3389/fonc.2023.1208089. eCollection 2023.
9
Enkurin: a novel marker for myeloproliferative neoplasms from platelet, megakaryocyte, and whole blood specimens.Enkurin:一种来自血小板、巨核细胞和全血标本的骨髓增殖性肿瘤新型标志物。
Blood Adv. 2023 Sep 26;7(18):5433-5445. doi: 10.1182/bloodadvances.2022008939.
10
Mutations, inflammation and phenotype of myeloproliferative neoplasms.骨髓增殖性肿瘤的突变、炎症与表型
Front Oncol. 2023 May 22;13:1196817. doi: 10.3389/fonc.2023.1196817. eCollection 2023.

本文引用的文献

1
Inhibition of Janus kinase-2 signalling pathway ameliorates portal hypertensive syndrome in partial portal hypertensive and liver cirrhosis rats.抑制Janus激酶-2信号通路可改善部分门静脉高压和肝硬化大鼠的门静脉高压综合征。
Dig Liver Dis. 2015 Apr;47(4):315-23. doi: 10.1016/j.dld.2014.12.017. Epub 2015 Jan 12.
2
Elevated levels of mast cells are involved in pruritus associated with polycythemia vera in JAK2V617F transgenic mice.在JAK2V617F转基因小鼠中,肥大细胞水平升高与真性红细胞增多症相关的瘙痒有关。
J Immunol. 2014 Jul 15;193(2):477-84. doi: 10.4049/jimmunol.1301946. Epub 2014 Jun 11.
3
Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients.骨髓增殖性肿瘤患者症状负担的显著聚类:1470 例患者的回顾性评估。
Blood. 2014 Jun 12;123(24):3803-10. doi: 10.1182/blood-2013-09-527903. Epub 2014 Feb 19.
4
Cytokine profiles in polycythemia vera and essential thrombocythemia patients: clinical implications.原发性血小板增多症和真性红细胞增多症患者的细胞因子谱:临床意义。
Exp Hematol. 2014 May;42(5):360-8. doi: 10.1016/j.exphem.2014.01.006. Epub 2014 Jan 23.
5
A phase II study of vorinostat (MK-0683) in patients with primary myelofibrosis and post-polycythemia vera myelofibrosis.伏立诺他(MK-0683)用于原发性骨髓纤维化和真性红细胞增多症后骨髓纤维化患者的II期研究。
Haematologica. 2014 Jan;99(1):e5-7. doi: 10.3324/haematol.2013.096669.
6
Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development?慢性炎症作为原发性血小板增多症、真性红细胞增多症和骨髓纤维化中突变的促进因素。一种人类炎症模型与癌症发展有关?
Leuk Res. 2013 Feb;37(2):214-20. doi: 10.1016/j.leukres.2012.10.020. Epub 2012 Nov 20.
7
Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs.骨髓增殖性肿瘤 (MPN) 症状评估表总症状评分:在 MPN 患者中前瞻性国际评估简化症状负担评分系统。
J Clin Oncol. 2012 Nov 20;30(33):4098-103. doi: 10.1200/JCO.2012.42.3863. Epub 2012 Oct 15.
8
Plasma cytokines in polycythemia vera: phenotypic correlates, prognostic relevance, and comparison with myelofibrosis.真性红细胞增多症患者血浆细胞因子:表型相关性、预后相关性及与骨髓纤维化的比较。
Am J Hematol. 2012 Nov;87(11):1003-5. doi: 10.1002/ajh.23295. Epub 2012 Sep 11.
9
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.芦可替尼治疗骨髓纤维化的双盲、安慰剂对照试验。
N Engl J Med. 2012 Mar 1;366(9):799-807. doi: 10.1056/NEJMoa1110557.
10
Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer?原发性骨髓纤维化、真性红细胞增多症和原发性血小板增多症中慢性炎症的观点:慢性炎症是克隆进化以及加速动脉粥样硬化和第二癌症发展的触发因素和驱动因素吗?
Blood. 2012 Apr 5;119(14):3219-25. doi: 10.1182/blood-2011-11-394775. Epub 2012 Feb 7.